In a study silencing endoglin using the GET of a plasmid-encoding shRNA against endoglin under a tissue-specific promoter in the same melanoma tumor model B16F10, complete, long-term regression was found in 44% of tumors. The gene discussed is ENG; the disease is neoplasm.